1062-49 Clinical outcome following percutaneous coronary intervention in patients with end-stage renal disease  by Toyofuku, Mamoru et al.
JACC March 3, 2004 ABSTRACTS - Angiography & Interventional Cardiology  49A
Angiography &
 Interventional Cardiology
serious cardiac and non-cardiac disease, their in-hospital clinical outcomes were consid-
erably better than those pts treated earlier. Greater selectivity in lesion revascularization
coupled with technical advances such as stents may contribute to these more favorable
results in this important pt population with CAD.
1062-48 Blood Glucose Level Predicts Severity of Renal and 
Myocardial Injury in Diabetic Patients Undergoing 
Coronary Interventions
Bryan J. Robertson, Joseph A. Gascho, Steven M. Ettinger, Ian C. Gilchrist, Mark Kozak, 
Charles E. Chambers, Patrick H. McNulty, Penn State- Milton S. Hershey Medical Center, 
Hershey, PA
Background: Patients with diabetes mellitus (DM) having percutaneous coronary inter-
ventions (PCI) are at increased risk for both contrast nephropathy and adverse cardiac
events. Theoretical considerations suggest glucose itself may mediate these risks by
synergizing with radiocontrast to initiate oxidative injury.
Methods: To test the hypothesis that pre-PCI serum glucose levels predict renal and
myocardial injury, we analyzed 558 DM patients who underwent PCI at our institution
from 1998 to 2002. We stratified 165 patients who had both a 48-hour peak serum creat-
inine (a marker of renal microvascular injury) and a 24-hour peak serum creatine phos-
phokinase (a marker of myocardial microvascular injury) into low glucose (<200 mg/dl,
n=88) and high glucose (>200 mg/dl, n=77) groups. The groups were similar in age (64+/
-14 versus (vs.) 65+/-12 years), gender (43% vs. 46% female), procedure (all balloon +/-
stent), contrast volume received (217+/-100 vs. 239+/-87 ml, p=0.16), and contrast type.
Results: Despite a trend toward better renal function in the high glucose group (creati-
nine=1.2+/-0.9 vs. 1.4+/-1.1 mg/dl, p=0.14), high glucose patients exhibited a greater
post-PCI rise in creatinine (0.26+/-0.5 vs. 0.17+/-0.5 mg/dl, p=0.15), a greater percent
increase in creatinine (21+/-39% vs. 12+/-27%, p=0.03), and a 5-fold higher chance of
suffering a >50% increase in creatinine (10% vs. 2%). High glucose patients were twice
as likely to have a non-Q wave myocardial infarction (40% vs. 21%) with a higher abso-
lute post-PCI CPK than low glucose patients (2666+/-390 vs. 1908+/-368 IU, p=0.07).
Even among patients without a non-Q wave myocardial infarction, high glucose patients
exhibited significantly greater post-PCI peak CPK’s (223+/-220 vs. 153+/-117 IU,
p=0.02).
Conclusion: Almost one-half of DM patients at our institution have blood glucoses >200
mg/dl at the time of PCI. Compared to matched patients with glucose <200 mg/dl, ele-
vated glucose patients exhibit a greater degree of both renal and myocardial injury after
PCI. Because correcting hyperglycemia prior to PCI is easy and inexpensive, the hypoth-
esis that euglycemia might improve outcomes from PCI in DM should be tested in a clini-
cal trial.
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Cardiovascular(CV) mortality remains high in end-stage renal disease(ESRD) with coro-
nary artery disease. Current developments of percutaneous coronary intervention (PCI)
devices may improve immediate and long term outcome in these high risk patients but
data were limited. Methods From the total of 1010 patients (age<80, 1500 lesions) who
underwent PCI between April 2000 to July 2002, we identified 100 patients (179 lesions)
with chronic dialysis. These were followed for one-year and compared with 100 age and
sex matched patients selected from control group. Results: In ESRD, lesions were more
extended (the number of diseased vessels: 1.9 vs. 1.7, p=0.01) and calcification was
more common (52% vs. 10%, p<0.001). The characteristics of procedure in ESRF were
more frequent use of rotablator (43% vs. 8%, p<0.001) and high utilization rate of stent
(74% vs. 73%, NS). In ESRF, the rates of procedural success (97% vs. 98% NS) and
one-year target lesion revascularization(TLR) (26% vs. 21%, NS) were similar in both
groups. However, in hospital death (5% vs. 1% p=0.001), new lesion development which
needed revascularization (27% vs. 10%, p=0.005), and one-year CV mortality rate (15%
vs. 2%, p<0.001) were markedly high in ESRD. In ESRD, factors concerning one-year CV
mortality were elevated CRP, diabetes, and AMI. Multivariate analysis showed elevated
CRP was the strongest predictor of CV mortality (RR2.7 per tertile of CRP, 95%CI 1.3-
5.8). CONCLUSION: The utilization of current PCI devices, such as stent and rotablator,
contributed to high procedural successful rate and acceptable restenosis rate in ESRD.
However, ESRF showed progressive development of new coronary artery lesions and
high mortality rate in short and long term. Elevated CRP was related to the poor progno-
sis.
POSTER SESSION
1063 
Coronary Stent: Adjunctive Strategies
Monday, March 08, 2004, 9:00 a.m.-11:00 a.m.
Morial Convention Center, Hall G
Presentation Hour: 9:00 a.m.-10:00 a.m.
1063-51 Clopidogrel Resistance Is Associated With Cytochrome 
3A Polymorphism
Jung W. Suh, Seoul National University Hospital, Seoul, South Korea
Background: Recent reports indicate that there are clopidogrel non-responders in the
population. Clopidogrel is transformed to its active metabolite by cytochrome P450 3A. A
single-nucleotide polymorphism (A6986G) in the CYP3A5 gene distinguishes an expres-
sor (A) and a reduced-expressor (G) allele and largely predicts CYP3A5 content in liver
and intestine. We postulate that clopidogrel resistance is associated with CYP3A5 poly-
morphism and investigated the relationship. Methods & Results: Patients (n=175) treated
clopidogrel after stenting were investigated. We analyzed single nucleotide polymor-
phism (A6986G) by polymerase chain reaction (PCR) and restriction enzyme digestion.
The genotype frequency was GG (97): AG (62): AA (16). The frequency of the GG geno-
type was 0.56, lower than that of Caucasians. But in nine patients who have developed
major adverse cardiac events within 3 months, the frequency of GG genotype was
0.89(GG: AG:AA=8:1:0). In the multivariate analysis including clinical and angiographic
characteristics, the GG genotype was a significant predictor of early MACE(MI, stroke,
SAT, death) after stenting (p=0.044). Follow up angiography was done at 6month
(n=140). The GG genotype was not significant predictor of in-stent restenosis. In order to
confirm the functional significance of the CYP3A5 polymorphism, we administered clopi-
dogrel (300mg loading and 75mg qd for 7days) to nine normal volunteers of AA, AG, GG
genotype (n=3 for each type). We performed platelet aggregation test (baseline, 4hr, 24hr
and 7days). There were tendency that platelet aggregation was more inhibited in the AA
type than non-AA type (AG+GG).Conclusion: CYP 3A5 polymorphism seems to be asso-
ciated with pharmacokinetics of clopidogrel and is associated with the early major
adverse cardiac event after coronary stenting . This polymorphism may explain the indi-
vidual difference in clopidogrel resistance.
1063-52 Lack of Efficacy of Clopidogrel Pretreatment in the 
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Background - Non-randomized studies on pre-treatment with ADP receptor blockers of
patients undergoing urgent stent implantation have suggested a reduction in myocardial
damage with pretreatment. In elective stenting the effect of pre-treatment with clopidogrel
has not yet been studied.
Methods - In a randomised trial 3 days pre-treatment with clopidogrel was compared to
standard post-procedural treatment, in addition to aspirin and heparin, in 203 patients
with stable coronary syndromes undergoing elective stentplacement. Primary endpoint
was a rise in troponin I and CK-MB 6 or 24 hours after stentplacement. Secondary end-
points were clinical endpoints at 24 hours, 1 month and 6 months after PCI and a com-
posite endpoint.
Results - No difference was found between not pre-treated and pre-treated patients in
the occurrence of elevation of CK-MB (respectively 6 (6.3%) vs. 7 (7.4%); p=0.78) or
troponin I (respectively 42 (43.3%) vs. 48 (51.1%); p=0.31). Adjustment for baseline val-
ues and possible confounding factors did not change these findings. The composite end-
point occurred in 47 (46.1%) of the not pre-treated patients and in 55 (54.5%) of the pre-
treated patients (p=0.26). Follow up showed no significant difference between the treat-
ment groups in the clinical endpoints.
Conclusion - In this randomized study no beneficial effect of pre-treatment with clopi-
dogrel on the elevation of troponin I, CK-MB or adverse cardiac events after 1 and 6
months could be demonstrated. Therefore we conclude that among patients with stable
coronary syndromes in whom stenting of coronary arteries is planned pre-treatment is
not mandatory in reducing early myocardial damage.
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Background: The optimal timing of noncardiac surgery (NCS) after coronary stenting
has not been determined. Earlier studies showed a high mortality rate due to stent throm-
bosis and perioperative hemorrhage when NCS is performed within two weeks of PCI.
Based on the known temporal course of stent reendothelization we devised the following
four step strategy: 1) A four-week course of clopidogrel post PCI 2) Deferral of elective
NCS for 5 to 12 weeks post stenting 3) Discontinuation of clopidogrel for a minimum of 5
days prior to surgery and 4) Use of heparin coated stents in high-risk patients. The pur-
pose of this study was to validate the clinical efficacy of this therapeutic strategy.
Methods: Forty six patients with significant CAD underwent PCI prior to planned NCS.
NCS was performed at a median of 48 (range: 39-89) days post PCI. All NCS were done
under general anesthesia and consisted of the following: Abdominal 35%, orthopedic
24%, vascular 15%, carotid 13%, thoracic 9% and miscellaneous 4%. In- hospital out-
